Lion Biotechnologies, Inc. (NASDAQ:IOVA)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a note issued to investors on Thursday. They presently have a $16.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 188.29% from the company’s previous close.

IOVA has been the topic of several other research reports. Oppenheimer Holdings, Inc. set a $13.00 target price on Lion Biotechnologies and gave the company a “buy” rating in a research note on Friday, August 18th. Chardan Capital boosted their price target on Lion Biotechnologies from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, May 4th. Zacks Investment Research cut Lion Biotechnologies from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Rodman & Renshaw began coverage on Lion Biotechnologies in a research note on Wednesday, May 10th. They issued a “buy” rating and a $13.00 price target for the company. Finally, Cowen and Company reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Lion Biotechnologies presently has a consensus rating of “Buy” and an average target price of $13.88.

Lion Biotechnologies (IOVA) traded up 0.90% during midday trading on Thursday, hitting $5.60. 331,246 shares of the company’s stock traded hands. The company has a 50 day moving average of $6.37 and a 200-day moving average of $6.68. Lion Biotechnologies has a 52 week low of $4.45 and a 52 week high of $8.81. The company’s market capitalization is $351.05 million.

ILLEGAL ACTIVITY WARNING: “Lion Biotechnologies’ (IOVA) “Buy” Rating Reiterated at HC Wainwright” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/lion-biotechnologies-iova-buy-rating-reiterated-at-hc-wainwright/1534636.html.

A number of large investors have recently bought and sold shares of the company. Broadfin Capital LLC acquired a new position in shares of Lion Biotechnologies during the second quarter worth approximately $16,731,000. California State Teachers Retirement System acquired a new position in shares of Lion Biotechnologies during the second quarter worth approximately $688,000. The Manufacturers Life Insurance Company acquired a new position in shares of Lion Biotechnologies during the second quarter worth approximately $308,000. Frazier Management LLC acquired a new position in shares of Lion Biotechnologies during the second quarter worth approximately $15,209,000. Finally, State Street Corp acquired a new position in shares of Lion Biotechnologies during the second quarter worth approximately $7,286,000. Hedge funds and other institutional investors own 76.00% of the company’s stock.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Analyst Recommendations for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.